Colorado News Desk

Idiopathic Pulmonary Fibrosis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Novartis, CSL Behring, AstraZeneca, Kadmon Pharmaceuticals, Calliditas Therapeutics, and others

 Breaking News
  • No posts were found

Idiopathic Pulmonary Fibrosis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Novartis, CSL Behring, AstraZeneca, Kadmon Pharmaceuticals, Calliditas Therapeutics, and others

December 06
21:02 2023
Idiopathic Pulmonary Fibrosis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Novartis, CSL Behring, AstraZeneca, Kadmon Pharmaceuticals, Calliditas Therapeutics, and others

DelveInsight’s, “Idiopathic Pulmonary Fibrosis Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the Idiopathic Pulmonary Fibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Idiopathic Pulmonary Fibrosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report

  • DelveInsight’s Idiopathic Pulmonary Fibrosis pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Idiopathic Pulmonary Fibrosis treatment.
  • The leading companies working in the Idiopathic Pulmonary Fibrosis Market include FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd., Ark Biosciences, Ocean Biomedical, and others.
  • Promising Idiopathic Pulmonary Fibrosis Pipeline Therapies in the various stages of development include DUB program: USP30 Inhibitor, LTI-03, TD-1058, PLN-74809, C21, GB0139, Pamrevlumab, PRM-151, KIN001-IPF, Treprostinil palmitil, AP01, BBT-877, and others.
  • December 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for BMS-986278. The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
  • December 2023: United Therapeutics announced a study of Phase 3 clinical trials for Inhaled Treprostinil. Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis.
  • November 2023: Modern Biosciences Ltd. announced a study of Phase 2 clinical trials for Leramistat. This will be a Phase 2, double-blind, placebo-controlled, 2-arm, parallel-group, multi-centre study to investigate leramistat treatment of patients aged 40 years or older with IPF.

 

Request a sample and discover the recent advances in Idiopathic Pulmonary Fibrosis Treatment Drugs @ Idiopathic Pulmonary Fibrosis Pipeline Report

 

In the Idiopathic Pulmonary Fibrosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Idiopathic Pulmonary Fibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Idiopathic Pulmonary Fibrosis Overview

Idiopathic pulmonary fibrosis (IPF) is a lung disorder where there is scarring of the lungs from an unknown cause. It is usually a progressive disease with a poor long-term prognosis. The classic features of the disorder include progressive dyspnea and a nonproductive cough. Pulmonary function tests usually reveal restrictive impairment and diminished carbon monoxide diffusing capacity.

 

Find out more about Idiopathic Pulmonary Fibrosis Treatment Landscape @ Drugs for Idiopathic Pulmonary Fibrosis Treatment

 

Idiopathic Pulmonary Fibrosis Emerging Drugs Profile

  • Pamrevlumab: FibroGen
  • Tipelukast: MediciNova
  • PLN-74809: Pliant Therapeutics
  • HZN-825: Horizon Pharmaceuticals
  • Brilaroxazine: Reviva Pharmaceuticals

 

Idiopathic Pulmonary Fibrosis Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies for Idiopathic Pulmonary Fibrosis. The Idiopathic Pulmonary Fibrosis companies which have their Idiopathic Pulmonary Fibrosis drug candidates in the most advanced stage, i.e. phase III include, FibroGen.

 

DelveInsight’s Idiopathic Pulmonary Fibrosis Pipeline Report covers around 80+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical

 

Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Learn more about the emerging Idiopathic Pulmonary Fibrosis Pipeline Therapies @ Idiopathic Pulmonary Fibrosis Clinical Trials Assessment

 

Scope of the Idiopathic Pulmonary Fibrosis Pipeline Report

  • Coverage- Global
  • Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Idiopathic Pulmonary Fibrosis Companies- FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd., Ark Biosciences, Ocean Biomedical, and others.
  • Idiopathic Pulmonary Fibrosis Pipeline Therapies- DUB program: USP30 Inhibitor, LTI-03, TD-1058, PLN-74809, C21, GB0139, Pamrevlumab, PRM-151, KIN001-IPF, Treprostinil palmitil, AP01, BBT-877, and others.

 

Dive deep into rich insights for new drugs for Idiopathic Pulmonary Fibrosis Treatment, Visit @ Idiopathic Pulmonary Fibrosis Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Idiopathic Pulmonary Fibrosis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Idiopathic Pulmonary Fibrosis – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. PRM-151: Hoffmann-La Roche
  9. Mid Stage Products (Phase II)
  10. Tipelukast: MediciNova
  11. Early Stage Products (Phase I/II)
  12. Lung stem cells: Regend Therapeutics
  13. Early Stage Products (Phase I)
  14. LTI-03: Lung Therapeutics
  15. Preclinical and Discovery Stage Products
  16. AD-214: Adalta
  17. Inactive Products
  18. Idiopathic Pulmonary Fibrosis Key Companies
  19. Idiopathic Pulmonary Fibrosis Key Products
  20. Idiopathic Pulmonary Fibrosis- Unmet Needs
  21. Idiopathic Pulmonary Fibrosis- Market Drivers and Barriers
  22. Idiopathic Pulmonary Fibrosis- Future Perspectives and Conclusion
  23. Idiopathic Pulmonary Fibrosis Analyst Views
  24. Idiopathic Pulmonary Fibrosis Key Companies
  25. Appendix

 

For further information on the Idiopathic Pulmonary Fibrosis Pipeline Therapeutics, reach out @ Idiopathic Pulmonary Fibrosis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market

Categories